Flora Migyanka is a nationally recognized breast cancer advocate, nonprofit founder, oncology professional, and 14-year survivor of invasive lobular breast cancer (ILC)—a disease that affects hundreds of thousands of women yet remains one of the most underfunded and underrecognized subtypes of breast cancer in the world.

Diagnosed in 2012 at age 40 while raising two young children, Flora faced her diagnosis with clarity and purpose. As a patient at the University of Michigan Breast Oncology Center, she underwent a bilateral mastectomy, reconstruction, and more than a decade of tamoxifen. Like so many women diagnosed with ILC, she quickly discovered a troubling reality: despite being the second most common subtype of breast cancer, lobular disease received less than 1% of dedicated breast cancer research funding. Rather than accept that silence, she decided to help change it.

In 2016, Flora partnered with her first cousin, Madeline Triffon—the first woman Master Sommelier in the United States—to launch Uncork for a Cure, a fundraising initiative that grew from a small community dinner into one of Michigan's premier culinary and wine events. What began as a conversation over a glass of champagne evolved into a movement. That movement became the Dynami Foundation.

Named after the Greek word for strength—a reflection of Flora's heritage and the women she serves—Dynami is a nonprofit organization dedicated to advancing invasive lobular breast cancer research, supporting women through treatment, and accelerating scientific collaboration. Under Flora's leadership, the Foundation has invested

MORE THAN

3 MILLION

in research and patient support initiatives, funding scientific partnerships, educational programs, patient assistance efforts, and innovative lobular breast cancer research at leading cancer centers across the country.

Flora's most significant milestone to date came when Dynami provided the catalytic seed funding to help launch the Lobular American Research Consortium (LARC)—the first coordinated national scientific consortium in the United States dedicated exclusively to invasive lobular breast cancer. LARC unites leading investigators from major academic institutions across the country to accelerate discovery, scientific collaboration, and progress for patients. The consortium represents the culmination of years of relationship-building among patients, researchers, physicians, industry leaders, and philanthropic partners dedicated to advancing lobular breast cancer research.

Over the past decade, Flora has worked alongside patients, physicians, researchers, industry leaders, and philanthropic partners to advance ILC awareness and science. She has championed research presented at the country's most prestigious oncology forums, including ASCO and the San Antonio Breast Cancer Symposium (SABCS), and continues to advocate for greater investment in precision medicine, biomarker development, and improved patient outcomes.

Flora's contributions extend beyond advocacy and philanthropy. In 2026, she served as a co-author on the peer-reviewed publication, Geographic Differences in Patient Experience After a Diagnosis of Lobular Breast Cancer, published in Annals of Surgical Oncology. Based on the experiences of more than 900 patients across North America and Europe, the study highlighted critical challenges in diagnosis, treatment, recurrence concerns, and survivorship for women living with invasive lobular breast cancer.

Flora is the recipient of the 2021 Barbara Ann Karmanos Cancer Institute Heroes for Cancer Community Service Award, serves in advocacy and advisory roles across the breast cancer community, and is featured in the book I Survived Cancer and Here Is How I Did It.

Professionally, she brings more than three decades of experience in oncology and the pharmaceutical industry. Her rare dual perspective—as both a long-term survivor and a seasoned oncology professional—allows her to uniquely bridge the worlds of science, medicine, philanthropy, and lived patient experience.

Proud of her Greek heritage, Flora named the foundation Dynami, the Greek word for strength—a value that continues to guide both her personal journey and the organization's mission.

Today, Flora continues to lead Dynami's national growth while championing a future where every woman diagnosed with invasive lobular breast cancer has access to better treatments, better research, and greater hope.